Darren Feldman

Section Head, Germ Cell Cancer · New York Presbyterian Hospital

Credentials: · · · ·

History

Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
National Cancer Institute · UG1
PI · $4.8M · Sloan-Kettering Inst Can Research
2019–2032

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2022–2027
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2018–2027
Germ Cell Tumor and Testicular Tumor DNA Registry
Principal investigator · Recruiting
Memorial Sloan Kettering Cancer Center
2014–2028
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2013–2027